- Home
- CANF vs EPIX Comparison
CANF vs EPIX Comparison
Compare CANF & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- EPIX
- Stock Information
- Founded
- CANF 1994
- EPIX 2009
- Country
- CANF Israel
- EPIX Canada
- Employees
- CANF N/A
- EPIX N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- EPIX Health Care
- Exchange
- CANF Nasdaq
- EPIX Nasdaq
- Market Cap
- CANF 9.6M
- EPIX 9.1M
- IPO Year
- CANF N/A
- EPIX N/A
- Fundamental
- Price
- CANF $0.65
- EPIX $0.20
- Analyst Decision
- CANF Strong Buy
- EPIX Hold
- Analyst Count
- CANF 2
- EPIX 3
- Target Price
- CANF $14.50
- EPIX $2.00
- AVG Volume (30 Days)
- CANF 171.1K
- EPIX 15.7M
- Earning Date
- CANF 08-26-2025
- EPIX 08-13-2025
- Dividend Yield
- CANF N/A
- EPIX N/A
- EPS Growth
- CANF N/A
- EPIX N/A
- EPS
- CANF N/A
- EPIX N/A
- Revenue
- CANF $560,000.00
- EPIX N/A
- Revenue This Year
- CANF $461.72
- EPIX N/A
- Revenue Next Year
- CANF N/A
- EPIX N/A
- P/E Ratio
- CANF N/A
- EPIX N/A
- Revenue Growth
- CANF N/A
- EPIX N/A
- 52 Week Low
- CANF $0.63
- EPIX $0.19
- 52 Week High
- CANF $3.12
- EPIX $7.41
- Technical
- Relative Strength Index (RSI)
- CANF 35.47
- EPIX 7.66
- Support Level
- CANF $0.64
- EPIX $0.19
- Resistance Level
- CANF $0.68
- EPIX $0.21
- Average True Range (ATR)
- CANF 0.02
- EPIX 0.02
- MACD
- CANF 0.01
- EPIX 0.02
- Stochastic Oscillator
- CANF 41.25
- EPIX 24.25
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.